PHARMACY

Publication honors Mirixa for information technology usage

BY Drew Buono

RESTON, Va. Mirixa was recently highlighted for its use of information technology in Gartner’s EXP CIO Signature, a publication targeted at chief information officers of major companies.

Mirixa operates by providing technology and supportive services to pharmacies, pharmacists and their patients through its Software-As-A-Service web-based solution, MirixaPro. Mirixa’s clinical solutions suite enables pharmacists to easily deliver patient care services in conjunction with health care providers to achieve improved patient outcomes, lower operating costs, and to produce patient care revenues in addition to pharmacies’ traditional dispensing and merchandising business.

“The perennial challenge for any CIO is how to align I.T. with the business,” said Mark Carberry, chief operating officer and chief information officer of Mirixa Corp. “What Mirixa has been able to do is develop a user-friendly I.T. platform to reach a critical sector of the healthcare industry—pharmacists—and provide them with services that generate a new revenue stream and work toward improving patient health, thereby enabling the business model for our company.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

New combination of drugs shown favorable in treating lupus

BY Diana Alickaj

NEW YORK A new study suggests that a combination of two potent drugs may serve as a new treatment for those who don’t respond to conventional Lupus treatments.

In the study, Ronald van Vollenhoven and colleagues at Karolinska University Hospital in Stockholm tested 16 female patients who did not respond to traditional lupus treatment, and were given, as a result, weekly infusions of rituximab for 4 weeks. The first and last infusions were combined with cyclophosphamide and a steroid, according to published reports.

It was found that after 6 months there was a significant decrease of SLE severity also known as systemic lupus erythematosus, which is an autoimmune disorder that damages the joints, kidneys, heart, lungs and blood.

Researchers noted that the presence of rituximab which targets B cells of the immune system, and cyclophsophamide, a strong immune suppressant drug, showed 50 percent improvement in disease severity, as well as causing the disease to go to remission in nine out of the thirteen patients.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Amgen, Roche battle over Mircera still unsettled

BY Diana Alickaj

In the long battle for Amgen to prevent generic drug company Roche Holdings from bringing its anemia drug Mircera into the US market, a federal appeals court has ruled that Roche could import its drug as long as it was not for sale, while also returning the case back to the International Trade Commission.

Amgen feels that since Roche applied for Mircera’s approval from the FDA, it was violating Amgen’s patents—for Epogen and Aranesp—because the application proved intent to sell. The FDA has already approved the drug but, according to published reports, it has not been marketed it in the US based on the legal matters involved.

As Drug Store News reported yesterday, Roche agreed to the U.S. District Court for Massachusetts’ conditions in an attempt to get Mircera on the market, including, according to published reports, paying Amgen a higher royalty fee. The court’s approval would give Amgen a new rival in the top selling Anemia market, which has made up more than 40 percent of Amgen’s revenue per year. Roche has agreed to set Mircera’s price at or below Epogen’s for the remainder of the patents that Amgen holds.

Amgen’s patents for its anemia drugs begin expiring in 2013, and, according to reports, Roche plans on waiting until then to sell its drug in the U.S. According to IMS Health, Aranesp had U.S. sales of $3.2 billion last year and Epogen had sales of $3.1 billion.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?